long term effects of semaglutides Two-year semaglutide in adults with overweight or obesity: the STEP 5 trial Common And Rare Side Effects
Description
The decreases previously observed in first-time AOM prescribing in November and December 2024 rebounded in January 2025
10.1016/S1474-4422(07)70327-7 333
The pharmaceutical industry is focusing on critical preparation areas to ensure successful market entry once patents expire, with supply chain security emerging as the primary challenge
Idiopathic intracranial hypertension: consensus guidelines on management
